Citizens JMP Reiterates Buy Ratings on Zevra Therapeutics, nCino with Target Prices

Citizens JMP and JMP Securities have reaffirmed positive ratings on two companies in the financial and biotech sectors. JMP Securities reiterated its 'Market Outperform' rating on nCino Inc., maintaining a $32.00 price target despite the stock's significant year-to-date decline, citing strong revenue growth and expected profitability within the year following insights gathered at the nSight user conference. Similarly, Citizens JMP reiterated a Buy rating on Zevra Therapeutics, highlighting its solid fiscal Q1 2025 results, including $20.4 million in net revenue and the sale of a Pediatric Rare Disease Priority Review Voucher for $150 million, which bolsters its development programs. Both firms emphasize confidence in their respective companies' long-term potential, with nCino positioned as a leading provider of cloud banking solutions and Zevra focusing on rare disease therapies. Analysts note that while Zevra shows promise, some investors may consider AI stocks for higher potential returns. These reaffirmations come amidst varied market performances and reflect a cautious yet optimistic outlook for these stocks.